Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 11 of 11 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/10/23
End: 10/31/24
Due: 10/31/25
Phase: N/A
Priority: Normal
Start: 03/25/24
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 10/15/20
End: 05/30/23
Due: 05/30/24
Phase: N/A
Priority: Normal
Start: 06/01/22
End: 01/26/23
Due: 01/26/24
Phase: N/A
Priority: Normal
Start: 10/15/20
End: 05/30/23
Due: 05/30/24
Phase: N/A
Priority: Normal
Start: 06/11/24
End: 11/30/25
Due: 11/30/26
Phase: N/A
Priority: Normal
Start: 06/08/23
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 12/13/21
End: 05/09/23
Due: 05/09/24
Phase: N/A
Priority: Normal
Start: 10/02/24
End: 10/09/26
Due: 10/09/27
Phase: N/A
Priority: Normal
Start: 02/03/22
End: 05/05/23
Due: 05/05/24
Phase: N/A
Priority: Normal
Start: 12/20/21
End: 12/09/22
Due: 12/09/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2b Study of ALTO-100 in MDD | NCT05712187 | Alto Neuroscience | user2@example.com | None | 2023-01-10 | 2024-10-31 | 2025-10-31 | - | - | 2025-07-14 |
| PD, PK, and Safety of ALTO-203 in Patients With MDD | NCT06391593 | Alto Neuroscience | user2@example.com | None | 2024-03-25 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |
| Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion | NCT04388189 | Alto Neuroscience | user2@example.com | None | 2020-10-15 | 2023-05-30 | 2024-05-30 | - | - | 2025-07-14 |
| Pilot Decentralized Trial | NCT05419869 | Alto Neuroscience | user2@example.com | None | 2022-06-01 | 2023-01-26 | 2024-01-26 | - | - | 2025-07-14 |
| Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram | NCT04388202 | Alto Neuroscience | user2@example.com | None | 2020-10-15 | 2023-05-30 | 2024-05-30 | - | - | 2025-07-14 |
| Study of ALTO-101 in Patients With Schizophrenia | NCT06502964 | Alto Neuroscience | user2@example.com | None | 2024-06-11 | 2025-11-30 | 2026-11-30 | - | - | 2025-07-14 |
| Study of ALTO-300 in MDD | NCT05922878 | Alto Neuroscience | user2@example.com | None | 2023-06-08 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |
| ALTO-300 in Depression | NCT05118750 | Alto Neuroscience | user2@example.com | None | 2021-12-13 | 2023-05-09 | 2024-05-09 | - | - | 2025-07-14 |
| ALTO-100 in Bipolar Disorder with Depression (BD-D) | NCT06656416 | Alto Neuroscience | user2@example.com | None | 2024-10-02 | 2026-10-09 | 2027-10-09 | - | - | 2025-07-14 |
| ALTO-300 in Depression (ALTO-300-004) | NCT05157945 | Alto Neuroscience | user2@example.com | None | 2022-02-03 | 2023-05-05 | 2024-05-05 | - | - | 2025-07-14 |
| ALTO-100 in MDD and/or PTSD | NCT05117632 | Alto Neuroscience | user2@example.com | None | 2021-12-20 | 2022-12-09 | 2023-12-09 | - | - | 2025-07-14 |